Joanne Berger-Sweeney facts for kids
Quick facts for kids
Joanne Berger-Sweeney
|
|
|---|---|
.jpg)
Joanne Berger-Sweeney in 2012
|
|
| Born |
Joanne E. Sweeney
September 21, 1958 Los Angeles, California
|
| Nationality | American |
| Education | Wellesley College (1979 BA) UC Berkeley (1981 MPH) Johns Hopkins Bloomberg School of Public Health (1989 PhD) |
| Known for | Proof-of-concept work on galantamine, a drug used to treat Alzheimer's disease |
| Spouse(s) | Urs V. Berger |
| Children | 2 |
| Awards | Alumni Achievement Award, Johns Hopkins University (2015) Posse Star, Posse Foundation (2017) |
| Scientific career | |
| Fields | Neuroscience |
| Institutions | Trinity College (Connecticut) |
| Doctoral advisor | Joseph T. Coyle Yvon Lamour |
| Doctoral students | Elizabeth A. Buffalo |
| Signature | |
 |
|
Joanne E. Berger-Sweeney (born September 21, 1958) is an American neuroscientist and the 22nd president of Trinity College, Hartford, Connecticut. She is the first African-American and the first woman to serve in the position. Earlier in her career, Berger-Sweeney did proof-of-concept work on galantamine (brand name Razadyne), the second-most used drug to treat Alzheimer's disease.
Contents
Early life and education
Berger-Sweeney was born on September 21, 1958, in Los Angeles. Her parents met at Clark College. Her father earned his law degree at Howard University, finishing second in his class. Her mother was executive director of the Los Angeles Girl Scouts Council and was the first African-American woman to lead a Girl Scouts Council in a major metropolitan area.
Berger-Sweeney attended Holman United Methodist Church in Los Angeles. Later in life, at her first commencement ceremony at Trinity College, Berger-Sweeney asked civil rights leader and former Holman UMC pastor Rev. James Morris Lawson Jr. to speak.
Berger-Sweeney attended Wellesley College, where she earned an undergraduate degree in psychobiology (neuroscience) in 1979. She received a Masters of Public Health from the University of California, Berkeley in 1981. Berger-Sweeney completed her doctoral work in neurotoxicology with Joseph T. Coyle at Johns Hopkins Bloomberg School of Public Health in 1989. Berger-Sweeney did proof-of-concept work on galantamine (brand name Razadyne), showing that the drug reversed memory deficits in mice. Her work served as the foundation for clinical trials by Janssen Pharmaceutica, culminating in the drug's approval by the FDA. Galantamine is the second-most-used Alzheimer's drug in the world.
Berger-Sweeney received her PhD in 1989. She completed her postdoctoral training at the National Institute of Health (Inserm) in Paris, France.
Career
Berger-Sweeney returned to Wellesley in 1991 to teach and conduct research. She was the first African-American woman at Wellesley to become a full professor and was named the Allene Lummis Russell Professor in Neuroscience. During her tenure at Wellesley, she served as director of the neuroscience program and as associate dean of the college.
In 2010, Berger-Sweeney became Dean of the School of Arts and Sciences at Tufts University, where she served until 2014, during which time she strengthened the school's faculty and interdisciplinary programs. She helped create the Center for Race and Democracy at Tufts, which studies the impact of race on individuals' lives. She also led the creation of the Bridge to Liberal Arts Success at Tufts (BLAST) program that supports college students from underserved high schools.
On October 26, 2014, she became the first woman and the first African American to lead Trinity College (Connecticut). In 2018, the college renewed her contract through 2024. Berger-Sweeney has overseen several important initiatives at Trinity, including a new strategic plan that will guide the college through 2023; a new mentoring program for incoming students (the Bantam Network); a new campus initiative to promote respect and inclusion; and an expansion into downtown Hartford.
Other leadership positions
Berger-Sweeney serves as a Director at Hartford Hospital, Inc and Hartford HealthCare Corporation. She chairs the professional development committee of the Society for Neuroscience, is on the board of directors for the AFS Intercultural Programs/USA, and is a Trustee and chair of the Academic Affairs Committee for Framingham State University. She is also a member of the board of trustees of Cold Spring Harbor Laboratory.
Research
Berger-Sweeney has received grants from the National Institutes of Health and the National Science Foundation, as well as from private foundations, for her work on the neurobiology of learning and memory, with applications to neurodevelopmental disorders. She has authored or co-authored more than 60 scientific articles.
Awards and honors
Berger-Sweeney has received a number of awards for her scientific work, including the following:
- Member, Sigma Xi (1992)
- Young Investigator Award, National Science Foundation (1994)
- Member, The Dana Alliance for Brain Initiatives
- Lifetime Mentoring Award, Society for Neuroscience (2006)
- Fellow, American Association for the Advancement of Science (2012)
- Distinguished Alumna Award, Johns Hopkins School of Public Health (2015)
- Member, American Academy of Arts and Sciences (2018)
Personal life
Berger-Sweeney's husband, Urs V. Berger, is a neuroscientist and computer scientist. They have two children.
Selected works
- (2014) Schaevitz L, Berger-Sweeney J, Ricceri L. "One-carbon metabolism in neurodevelopmental disorders: using broad-based nutraceutics to treat cognitive deficits in complex spectrum disorders". Neuroscience and Biobehavioral Reviews. 46: 270–84. PubMed DOI: 10.1016/j.neubiorev.2014.04.007
- (2012) Schaevitz LR, Berger-Sweeney JE. "Gene-environment interactions and epigenetic pathways in autism: the importance of one-carbon metabolism". Ilar Journal / National Research Council, Institute of Laboratory Animal Resources. 53: 322–40. PubMed DOI: 10.1093/ilar.53.3-4.322
- (2011) Berger-Sweeney J. "Cognitive deficits in Rett syndrome: what we know and what we need to know to treat them". Neurobiology of Learning and Memory. 96: 637–46.
- (2009) Ward BC, Kolodny NH, Nag N, Berger-Sweeney JE. "Neurochemical changes in a mouse model of Rett syndrome: changes over time and in response to perinatal choline nutritional supplementation". Journal of Neurochemistry. 108: 361–71. PubMed DOI: 10.1111/j.1471-4159.2008.05768.x
- (2008) Nag N, Mellott TJ, Berger-Sweeney JE. "Effects of postnatal dietary choline supplementation on motor regional brain volume and growth factor expression in a mouse model of Rett syndrome". Brain Research. 1237: 101–9. PubMed DOI: 10.1016/j.brainres.2008.08.042
